UB-612
Vaccine candidate against COVID-19
- DB16444
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
| Medical response |
|
 COVID-19 portal |
|
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia [zh], and Vaxxinity, Inc.[1] It is a peptide vaccine.[2][3]
It is composed of SARS-CoV-2 S1-RBD protein and synthetic peptides representing T cell (Th and CTL) epitopes on the nucleocapsid, spike and membrane proteins. The multitope composition is differentiated from other solely spike-protein based vaccines. By recognition against epitopes on Spike (S1-RBD and S2) and non-Spike (N and M) structure proteins, UB-612 provides B-cell and T-cell memory immunity and offers a potential as a universal vaccine to fend off the Omicron variant and new emerging variants of concern.[4][5] Vaxxinity began seeking regulatory approval for UB-612 for use as a booster vaccine in the United Kingdom and Australia in 2022.[6][7]
Technology
UB-612 is a peptide vaccine incorporating multiple epitopes, including the spike protein receptor binding domain as well as other virus structural proteins.[1][3] The spike protein peptide is fused to an Fc domain of single-chain IgG1, and the other six peptides are derived from highly conserved sequences from the spike, nucleocapsid, and membrane proteins of SARS-CoV-1 and SARS-CoV-2. It also contains a proprietary UBITh1 peptide derived from the measles virus fusion protein, CpG oligonucleotides, and aluminum phosphate adjuvant to improve the immune response. It is produced in CHO cells.[2]
Clinical trials
In September 2020, phase I clinical trials of UB-612 started in Taiwan.[8] and in January 2021, phase II clinical trials began in Taiwan.[9] In February 2021, phase II/III clinical trials began.[10] Results from clinical trials showing positive safety and efficacy data were published in May 2022,[4] and in May-June 2023.[11][12]
In March 2022, Vaxxinity started an international phase III clinical trial of UB-612 as a heterologous booster vaccine against three approved platforms: mRNA, adenovirus vector, and inactivated virus.[13] The company announced positive topline data of the trial in December 2022[14] and positive results were published in January 2024.[15]
References
- ^ a b Liao G (27 June 2021). "Taiwan's second domestic COVID vaccine's midterm performance in phase II trials inferior to local competitor: experts". Taiwan News. Retrieved 8 July 2021.
- ^ a b Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L (12 July 2021). "SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants". Frontiers in Immunology. 12: 701501. doi:10.3389/fimmu.2021.701501. PMC 8311925. PMID 34322129.
- ^ a b "COVID-19 Vaccine". Vaxxinity. Archived from the original on 9 October 2021. Retrieved 9 October 2021.
- ^ a b Wang CY, Hwang KP, Kuo HK, Peng WJ, Shen YH, Kuo BS, et al. (May 2022). "A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants". The Journal of Clinical Investigation. 132 (10). doi:10.1172/JCI157707. PMC 9106357. PMID 35316221.
- ^ Guirakhoo F, Wang S, Wang CY, Kuo HK, Peng WJ, Liu H, et al. (October 2022). "High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster". The Journal of Infectious Diseases. 226 (8): 1401–1406. doi:10.1093/infdis/jiac241. PMC 9278180. PMID 35723969.
- ^ Lynch R (9 February 2023). "Vaxxinity moves HQ, jobs to Florida's Space Coast from Texas". Orlando Business Journal. American City Business Journals. Retrieved 26 February 2023.
- ^ Lorenz J (2 November 2022). "Phase 3 Trial of Vaxxinity's COVID-19 Vaccine as a Heterologous Booster Advances". ContagionLive. Retrieved 26 February 2023.
- ^ Clinical trial number NCT04545749 for "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine" at ClinicalTrials.gov
- ^ Clinical trial number NCT04683224 for "A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine" at ClinicalTrials.gov
- ^ Clinical trial number NCT04773067 for "A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers" at ClinicalTrials.gov
- ^ Wang CY, Peng WJ, Kuo BS, Ho YH, Wang MS, Yang YT, et al. (April 2023). Krammer F (ed.). "Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses". PLOS Pathogens. 19 (4): e1010870. doi:10.1371/journal.ppat.1010870. PMC 10153712. PMID 37079651.
- ^ Wang CY, Kuo BS, Lee YH, Ho YH, Pan YH, Yang YT, et al. (June 2023). "Targeting Multiple Conserved T-Cell Epitopes for Protection against COVID-19 Moderate-Severe Disease by a Pan-Sarbecovirus Vaccine". medRxiv.
- ^ Clinical trial number NCT05293665 for "Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine" at ClinicalTrials.gov
- ^ "Vaxxinity's Phase III Covid-19 booster trial meets endpoints". Clinical Trials Arena. 5 December 2022. Retrieved 25 February 2023.
- ^ Wang CY, Kuo BS, Lee YH, Ho YH, Pan YH, Yang YT, et al. (February 2024). "UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease". iScience. 27 (2): 108887. doi:10.1016/j.isci.2024.108887. PMC 10839960. PMID 38318376.
External links
Scholia has a profile for UB-612 (Q100158046).
Portals:
Medicine
Viruses
COVID-19
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
